このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comprehensive Lung Health (CLUES)

2026年11月6日 更新者:Ankit Bharat、Northwestern University

Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification

Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.

調査の概要

状態

募集

研究の種類

介入

入学 (推定)

10000

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Northwestern Medicine
        • 主任研究者:
          • Ankit Bharat, MD
        • コンタクト:
        • 副調査官:
          • Momen Wahidi, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

21年~85年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

All Cohorts:

•Adults 21 through 85 years of age.

Cohort 1:

•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.

Cohort 2:

•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.

Cohort 3:

  • Asymptomatic individuals who:
  • Do not have a clinical indication for chest CT
  • Do not meet current USPSTF criteria for LDCT lung cancer screening
  • Able to provide informed consent

Exclusion Criteria:

All Cohorts:

•Individuals below the age of 21 and above the age of 85.

Cohort 3:

  • Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
  • Any chest CT within the prior 2 years
  • Pregnancy
  • In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
  • Unable to provide informed consent or lacks decision-making capacity
  • McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ふるい分け
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Cohort 1 (Medical Indication Group)

Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

介入なし:Cohort 2 (Guideline-Based Screening Group)

Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

アクティブコンパレータ:Cohort 3 (Asymptomatic Research LDCT Group)

Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study.

A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.

他の名前:
  • LDCT

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Primary Endpoint
時間枠:For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

二次結果の測定

結果測定
メジャーの説明
時間枠
Secondary Endpoint 1
時間枠:For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 2
時間枠:For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 3
時間枠:For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 4
時間枠:For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Associations between baseline defined variables and LDCT-detectable findings.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 5
時間枠:5 years

EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available.

5 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Exploratory Endpoint 1
時間枠:6 years

Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories.

6 years
Exploratory Endpoint 2
時間枠:6 years

Exploratory prediction models if event counts support model development.

6 years
Exploratory Endpoint 3
時間枠:6 years

Descriptive analyses of downstream clinical evaluation after baseline CT findings.

6 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ankit J Bharat, MD、Northwestern Medicine Canning Thoracic Institute
  • 主任研究者:Momen J Wahidi, MD、Northwestern Medicine Canning Thoracic Institute

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月16日

一次修了 (推定)

2030年9月16日

研究の完了 (推定)

2031年12月30日

試験登録日

最初に提出

2026年11月6日

QC基準を満たした最初の提出物

2026年11月6日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する